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Abstract
A distinctive feature of HCV is that its life cycle depends on lipoprotein metabolism. Viral morphogenesis and secretion
follow the very low-density lipoprotein (VLDL) biogenesis pathway and, consequently, infectious HCV in the serum is
associated with triglyceride-rich lipoproteins (TRL). Lipoprotein lipase (LPL) hydrolyzes TRL within chylomicrons and VLDL
but, independently of its catalytic activity, it has a bridging activity, mediating the hepatic uptake of chylomicrons and VLDL
remnants. We previously showed that exogenously added LPL increases HCV binding to hepatoma cells by acting as a
bridge between virus-associated lipoproteins and cell surface heparan sulfate, while simultaneously decreasing infection
levels. We show here that LPL efficiently inhibits cell infection with two HCV strains produced in hepatoma cells or in
primary human hepatocytes transplanted into uPA-SCID mice with fully functional human ApoB-lipoprotein profiles. Viruses
produced in vitro or in vivo were separated on iodixanol gradients into low and higher density populations, and the
infection of Huh 7.5 cells by both virus populations was inhibited by LPL. The effect of LPL depended on its enzymatic
activity. However, the lipase inhibitor tetrahydrolipstatin restored only a minor part of HCV infectivity, suggesting an
important role of the LPL bridging function in the inhibition of infection. We followed HCV cell entry by immunoelectron
microscopy with anti-envelope and anti-core antibodies. These analyses demonstrated the internalization of virus particles
into hepatoma cells and their presence in intracellular vesicles and associated with lipid droplets. In the presence of LPL,
HCV was retained at the cell surface. We conclude that LPL efficiently inhibits HCV infection by acting on TRL associated
with HCV particles through mechanisms involving its lipolytic function, but mostly its bridging function. These mechanisms
lead to immobilization of the virus at the cell surface. HCV-associated lipoproteins may therefore be a promising target for
the development of new therapeutic approaches.
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Introduction
HCV hepatitis C virus (HCV) infection is a major cause of liver
disease worldwide. In most cases, HCV infection progresses to
chronic liver disease, which can lead to liver cirrhosis and
hepatocarcinoma [1]. There is still no vaccine available, and
current therapies have only limited efficacy, depending on the
virus genotype, and are associated with several side effects [2,3].
HCV is an enveloped virus of the Flaviviridae family (genus
Hepacivirus) with a single-stranded positive RNA genome of about
9.6 kb. The viral genome encodes a polyprotein composed of
about 3,000 amino acids, which is cleaved by the host and viral
proteases into three structural proteins (the capsid protein, and two
envelope glycoproteins E1 and E2), P7 and several nonstructural
proteins (NS2, NS3, NS4A, NS4B, NS5A and NS5B). The
structural proteins form the virus particles, whereas nonstructural
proteins NS3 to NS5 are involved in genome replication and virus
assembly (reviewed in [4]).
A distinctive feature of the HCV life-cycle is that viral RNA
replication depends on cholesterol and fatty acid biosynthesis
[5,6,7]. In addition, the assembly and secretion of viral progeny
are closely related to the VLDL biogenesis pathway [5,7,8,9].
Chronic HCV infection thus induces changes in host lipid
metabolism, such as a decrease in serum lipoprotein levels and
an accumulation of lipids in liver parenchymal cells (steatosis)
[10,11,12].
HCV particles contain the nucleocapsid and the envelope E1
and E2 glycoproteins. Nevertheless, most of the HCV in the serum
of patients is of low density [13,14] and has a VLDL-like structure.
Indeed, it has been suggested that HCV is a hybrid particle
composed of TRL containing ApoB and ApoE, in which the HCV
nucleocapsids and virus envelope glycoproteins are embedded
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(LVPs), constitute the most infectious population of HCV, as
shown by studies in a chimpanzee [14] and in cell culture models
[15,17]. The association of cholesterol and sphingolipids with
HCV is essential for virus maturation and infectivity [18,19].
Due to the crucial role of lipoproteins in the virus cell cycle,
there is increasing evidence that a powerful tool for studying HCV
infection — a cell culture–derived HCV (HCVcc) allowing in vitro
replication and the production of infectious virus particles — does
not accurately reflect the real infection process in terms of the
lipoprotein composition of the virus and host cell phenotype.
Indeed, comparative analyses of the viruses produced in hepatoma
cells and in experimental models showed that the HCV produced
in vivo had a lower density and a higher specific infectivity [20] and
fusogenic capacity [21] than HCVcc produced in vitro.
The data currently available suggest that lipoproteins integrated
into viral particles play an important role in virus uptake into the
hepatocyte (for review, see [22]). The initiation of a productive
HCV infection involves several cellular factors that trigger virus
uptake via tight junctions, and three of the major molecules
mediating HCV cell entry, the scavenger receptor (SR-BI), the
LDL-receptor (LDL-R) and heparan sulfate proteoglycans (HSPG)
also interact with lipoproteins or lipids.
The essential role of lipoproteins in the HCV life cycle led us to
investigate the role of lipoprotein lipase in viral uptake and HCV
infection. LPL is a lipolytic enzyme (EC 3.1.1.34) that hydrolyzes
lipids in TRL present in chylomicrons and VLDL [23]. LPL is
produced by muscle and adipose tissue, but is specifically found
attached to the endothelial cells lining capillaries on the luminal
side, where it catalyzes the lipolysis of ApoB- and ApoE-containing
lipoproteins. Hydrolysis of the triacylglycerol component of
circulating TRL provides fatty acids for peripheral tissues, which
are internalized via CD-36 [24,25,26].
In addition to its catalytic function as a triglyceride hydrolase,
the homodimeric form of LPL has a second, ‘‘structural’’ function,
as a bridging factor for lipoprotein uptake by the hepatocyte,
probably leading to the cellular catabolism of lipoproteins [26,27].
This function of LPL mediates the hepatic clearance of VLDL and
chylomicron remnants independent of the lipolytic function of the
enzyme: indeed, enhanced lipoprotein uptake is not affected by
inhibitors of its lipolytic activity in either in vitro or in vivo models
[24,27,28]. The enzyme promotes the hepatic uptake of
lipoproteins via liver HSPG (syndecan-1) alone [26,29,30] or
HSPG interacting with lipoprotein receptors: LDL-R, LRP
[25,28] or SR-BI [31].
In a previous study, we showed that LPL enhances the binding
of HCV from the sera of patients to various cell types, including
hepatoma cell lines [32]. Like the mechanisms operating for
lipoproteins, the mechanisms of action of LPL on HCV involved
the formation of a bridge by the dimeric form of LPL between
virus-associated lipoproteins and cell-surface HSPG. Our previous
observations also showed an inhibitory effect of LPL on HCV
infection in the HCV cell culture model (HCVcc) [32].
This intriguing observation led us to investigate further the
influence of LPL on cell infection by HCV. We first compared the
effect of LPL on cell infection with different HCV strains produced
in vitro in hepatoma cells (which have defective lipoprotein
metabolism) with its effect on cell infection by the virus produced
in primary human hepatocytes transplanted into uPA/SCID mice,
a model mimicking the natural infection of differentiated human
hepatocytes with normal lipid and lipoprotein metabolism
[33,34,35,36]. We then analyzed the mechanism of action of
LPL on HCV infection, which involves the LPL catalytic function,
but is dependent mostly on the structural function of the enzyme.
Our immunoelectron microscopy studies showed that LPL inhibits
HCV cell entry, blocking the virus at the cell surface.
Materials and Methods
Cell culture
Human Huh7.5 hepatoma cells (kindly provided by C. Rice)
were grown in Dulbecco’s modified Eagle’s medium (DMEM;
Invitrogen, Cergy Pontoise, France) supplemented with sodium
pyruvate, 10% fetal calf serum, glutamine, antibiotics, antifungal
agents and non essential amino acids. Cells were maintained at
37uC, under an atmosphere containing 5% CO2.
Virus strains
The plasmid encoding the genome of the JFH-1 strain was used
to generate HCVcc. The virus was cultured as previously
described [37], to obtain a viral stock of 10
7 IU/ml.
The pFI-J6J plasmid, used to generate the J6/JFH-1 virus
strain, was kindly provided by C. Rice. JFH-1/J6 HCV genomic
RNA was obtained from purified pFI-J6J with the T7 Ribomax
Express large-scale RNA production system (Promega). Huh7.5
cells were transfected and cultured as previously described [38], to
obtain a viral stock of 7.9610
6 IU/ml.
Cell infection with HCV in the presence and absence of
LPL
Confluent monolayers of Huh7.5 cells were grown for 48 h in
six-well tissue culture plates to obtain approximately 10
6 cells/well.
Cells were incubated with 25 ml of the virus preparations for 2 h at
37uC to allow infection. Cells were washed and grown in complete
DMEM for 24 h or 48 h at 37uC. Total RNA was then extracted
and HCV RNA levels were determined by quantitative RT-PCR.
Data were normalized with respect to the cellular gene GAPDH,
using the GAPDH Control Kit (Eurogentec, Angers, France). All
assays were performed at least in triplicate. HCV RNA levels are
expressed in IU relative to a HCV RNA quantification panel from
Acrometrix (Berkeley, CA, USA).
We assessed the effect of lipoprotein lipase on HCV infection,
by incubating Huh7.5 cells with 1 mg/ml bovine LPL (Sigma)
diluted in complete DMEM for 30 min at 4uC before adding the
virus.
For investigation of the enzymatic effect of LPL, Huh7.5 cells
were incubated for 30 min at 4uC with 1 mg/ml LPL diluted in
complete DMEM in the presence of a lipase inhibitor, tetrahy-
drolipstatin (THL, Calbiochem, Darmstadt, Germany) at a final
concentration of 50 mg/ml, before adding the virus. Inoculation
was carried out for 2 h at 37uC. Cells were then washed and
grown in complete DMEM for 24 h or 48 h. Total RNA was
extracted and HCV RNA levels were determined by quantitative
RT-PCR. Data were normalized with respect to GAPDH, as
described above.
Quantitative RT-PCR (RT-qPCR)
The HCV RNA associated with cells was quantified by one-step
quantitative RT-PCR with the SuperScript III Platinum One-Step
qRT-PCR Kit (Invitrogen). The 59-AGYGTTGGGTYGC-
GAAAG-39 and 59-CACTCGCAAGCRCCCT-39 primers were
used to amplify the HCV RNA from JFH clones, and 6-FAM-
CCTTGTGGTACTGCCTGA-MGB (Applied Biosystems, Fos-
ter City, CA, USA) was used as an internal probe. Real-time
detection of the PCR products was carried out with an AbiPrism
7000. HCV RNA was quantified relative to a reference viral stock
and standardized with an HCV RNA quantification panel from
AcroMetrix. RNA levels are expressed as HCV RNA IU.
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JFH-1 HCVcc
uPA-SCID mice with engrafted human liver cells were
generated as previously described [33,34]. Briefly, 10
6 cryopre-
served primary human hepatocytes (BD Biosciences, Erembode-
gem, Belgium) were transplanted into two-week old uPA
+/+-SCID
mice. Two months later, the concentration of human albumin in
mouse plasma was quantified, to assess the numbers of human
hepatocytes engrafted into the mouse liver (Bethyl Laboratories
Inc., Montgomery, TX, USA). Chimeric mice were infected with a
virus stock prepared from a concentrated cell culture supernatant
containing JFH-1 at a final concentration of 10
9 IU/ml and/or
J6/JFH-1 at a concentration of 7.9610
6 IU/ml.
The JFH-1 preparation produced in mice (mJFH-1) was
generated by pooling all plasma samples collected between 1
and 12 weeks after inoculation. A pool of plasma from J6/JFH-1-
infected mice (mJ6/JFH-1) was obtained by combining samples
collected between days 7 and 38 post-infection. The viral titers of
the mJFH-1 and mJ6/JFH-1 pools were 5.85610
5 IU/ml and
7.82610
7 IU/ml, respectively, as determined with the Roche
COBAS Ampliprep – COBAS TaqMan HCV test (Roche
Diagnostics, Vilvoorde, Belgium).
Ethics Statement
This study was carried out in strict accordance with the
recommendations for the care and use of the laboratory animals of
the European Community (Directive 86/609/EEC). The protocol
was approved by the Animal Ethics Committee of the Faculty of
Medicine and Health Sciences, Ghent University, Belgium (Permit
Number EDC06/07). During surgery, the animals were anesthe-
tized with isoflurane and all possible efforts were made to
minimize suffering.
Ultracentrifugation through iodixanol gradients
Discontinuous 5-50% iodixanol density gradients (OptiPrep,
Sigma) were prepared from five buffered solutions of iodixanol in
HEPES-buffered saline (Sigma). Samples were overlaid onto the
gradients and centrifuged for 22 h at 4uC and 50,000 rpm in a
SW60Ti rotor in a Beckman Coulter Optima L-90 K ultracen-
trifuge. Fractions (50 ml each) were collected and their density was
determined with a refractometer (Atago CO LTD, Tokyo, Japan).
Determination of HCV infectivity
We determined the infectivity of the viral preparation, by
infecting Huh7.5 cells (10
5 per well in a 24-well plate) with 25 mlo f
each virus fraction and incubating for 48 h at 37uC. Total RNA
was extracted and HCV-RNA levels were quantified by
quantitative RT-PCR. The results were normalized, taking into
account the initial HCV-RNA content of each of the samples
analyzed by RT-qPCR.
Determination of cellular lipid mass in the presence and
absence of LPL
Huh7.5 cells (0.2610
6 cells/well) were used to seed 24-well
plates, which were incubated for 24 h at 37uC. Cells were then
washed with cold PBS and incubated for 5 min on ice with cold
serum-free medium before adding 5 mg/ml bovine LPL (Sigma),
with or without 50 mg/ml LPL inhibitor, tetrahydrolipstatin
(THL), (Sigma). After incubation on ice for 20 minutes, 50 mg/
ml human VLDL-Prot (d,1.006 g/ml) isolated from normolipi-
demic plasma by preparative ultracentrifugation [39] was added to
the culture medium, which was then incubated for an additional
30 minutes on ice. When required, cells were incubated with
10 U/ml heparin (Choay) for 10 min on ice and then for 2 hours
at 37uC. Total cellular triglycerides and cholesterol mass were
quantified as previously described [40].
Electron microscopy
Supernatants from Huh7.5 cells producing JFH1 HCVcc were
concentrated by centrifugation through a 20% sucrose cushion for
4 h at 4uC and 32,000 rpm, in a SW32Ti rotor.
Huh7.5 cells were grown in 3 cm dishes for 24 h, washed with
cold serum-free DMEM and maintained for 10 min at 4uC before
replacing the medium with 1 ml cold serum with or without
DMEM and 1 mg of LPL, and incubating for a further 20 min at
4uC. Concentrated virus preparation (containing 5610
9 IU/ml of
HCV RNA) was then added and incubated with cells for 30 min
at 4uC. At the end of this adsorption step at 4uC, cells were either
washed immediately (T0) or placed at 37uC for 5 min (T5),
10 min (T10) or 20 min (T20). Cells were then prepared for
transmission electron microscopy (TEM) examination. They were
lightly fixed by incubation with 4% (v/v) paraformaldehyde (Delta
Microscopies, Ayguevive, France) and 0.05% (v/v) glutaraldehyde
in phosphate-buffered saline (PBS) at pH 7.4, for 30 min at 37uC.
They were then thoroughly washed with PBS and incubated for
10 min in blocking solution composed of 0.5% v/v cold fish skin
gelatin (FSG), 0.1% v/v saponin and 0.02 M glycine (all from
Sigma Aldrich) in PBS pH 7.4, at room temperature. For control
experiments, saponin-free buffer was used. After washing with
0.5% FSG in PBS (PBS/FSG), cells were incubated for 60 min
with primary monoclonal antibodies diluted in PBS/FSG: anti-E2
AP-33, (diluted 1:1500), kindly provided by A. Patel, or ACAP-27
(0.6 mg/ml), kindly provided by JF. Delagneau, or anti-LPL
(Sigma, at a concentration of 1.66 mg/ml). After washing in PBS/
FSG, cells were then incubated for 30 min with secondary, anti-
mouse IgG antibody conjugated with NanogoldH particles
(Yaphank, NY, USA) in PBS/FSG (1:75), washed extensively in
PBS/FSG and fixed by incubation with 1% v/v glutaraldehyde in
PBS, for 1 h, at room temperature. Silver enhancement of
NanogoldH was carried out for 3 min, after washing in distilled
water, with the HQ silver enhancement kit (Nanoprobe, Yaphank,
NY, USA) according to the manufacturer’s instructions. Cells were
then post-fixed by incubation with 1% v/v osmium tetroxide in
PBS for 1 h and processed by dehydration in ethanol for
embedding in epoxy resin. TEM examination was performed on
a Philips CM120 microscope operating at 80 kV, and images were
acquired with an ORIUS SC200D CCD camera (Gatan Inc.).
HCV-bound gold particles were quantified in LPL-treated and
non treated preparations, for each time point. We examined 30
cells in each case and determined the number of intra- or
extracellular gold particles.
Other assays
HCV core antigen was determined in gradient fractions with
the HCV Core Antigen ELISA kit (WAKO Chemicals, Ortho-
Clinical Diagnostics, Germany). Apolipoprotein B was assayed
with the AssayMax Human Apolipoprotein B ELISA kit
(AssayPro, St. Charles, MO, USA) and cholesterol was quantified
with the AmplexH Red Cholesterol Assay Kit (Invitrogen).
Results
LPL inhibits infection with two HCVcc strains produced in
Huh7.5 cells
As hepatic cells do not produce LPL, we used bovine LPL to
investigate the effect of exogenously added enzyme on virus
multiplication in Huh7.5 cells. This cell line is capable of
Inhibition of HCV Infection by Lipoprotein Lipase
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human LPL and is thus often used in studies on the role of LPL in
interactions of lipoproteins with cells [41]. Our previous
experiments suggested that LPL inhibited cell infection with
HCVcc (JFH-1 strain), with a large decrease in virus production
observed 24 h, 48 h and 72 h post-infection [32]. We extended
this observation, using another virus strain, J6/JFH-1, which also
replicates in Huh7.5 cells. The JFH-1 strain is based on a cloned
genotype 2a HCV RNA isolated from a patient with fulminant
hepatitis C [37], whereas, in the chimeric J6/JFH-1 strain, the
genes encoding the structural (E1,E2,core), p7 and NS2 proteins
are derived from another virus, of genotype 2a (HC-J6) [38].
We investigated the effect of LPL on cell infection with these
two HCVcc strains, by incubating Huh7.5 cells with bovine LPL
for 30 min at 4uC before adding the virus, and determining
intracellular HCV RNA levels 24 h after infection, as previously
described [32]. The infection of cells with the two virus strains was
inhibited by more than 90% in the presence of LPL (Figure 1A).
This inhibition was also observed 48 and 72 h after infection.
Thus, the addition of LPL to Huh7.5 cells as an exogenous ligand
inhibited cell infection with various HCVcc strains.
LPL inhibits cell infection with HCV produced in primary
human hepatocytes transplanted into chimeric uPA-SCID
mice
Lipids and lipoproteins are required for HCV replication, and
for the morphogenesis and secretion of infectious virus particles
[5,6,7,42]. The Huh7.5 cell line commonly used to propagate
HCV in cell culture differs in several ways, in terms of its
lipoprotein metabolism, from human primary hepatocytes
[42,43,44,45]. Indeed, this cell line secretes relatively dense,
lipid-poor ApoB-containing lipoprotein particles, unlike the VLDL
produced in vivo by the human liver. Uncertainties therefore
remain concerning the extent to which the HCVcc produced in
these cells resembles real, lipoprotein associated HCV. It was
therefore important to determine whether our observations with
HCVcc produced in cell culture were relevant to virus produced in
primary human hepatocytes.
We investigated whether LPL inhibited cell infection with the
same virus strains produced in primary human hepatocytes
transplanted into chimeric mice. In this model, severe combined
immunodeficiency disorder (SCID) mice carry a urokinase-type
plasminogen activator transgene controlled by an albumin
promoter (Alb-uPA), inducing a hepatocyte-lethal phenotype. It
is therefore possible to transplant primary human hepatocytes into
uPA-SCID mice. Repopulation occurs in a well organized fashion
and the mice display human-type liver metabolism and can be
infected with HCV of various genotypes [33,34]. Importantly, the
viral particles produced in these mice have characteristics similar
to those of viruses isolated from HCV-infected chimpanzees and
patients with chronic HCV infection [20].
The JFH-1 and J6/JFH-1 HCVcc strains produced in Huh7.5
cells were concentrated and injected into chimeric uPA-SCID
mice, to infect transplanted human primary hepatocytes. We
assessed the ability of pooled serum samples from infected mice
(designated mJFH-1 and mJ6/JFH-1) to infect Huh7.5 cells in the
presence or absence of LPL. Cell infection with these two virus
strains produced in chimeric mice was strongly inhibited in the
presence of LPL, like infection with viruses produced in Huh7.5
cells (Figure 1 A,B).
Thus, exogenously added LPL has a potent inhibitory effect on
cell infection with HCV produced in hepatoma cells in vitro or in vivo
in human primary hepatocytes transplanted into chimeric mice.
Analysis of viruses produced in vitro and in vivo
HCV particles produced in vitro [20,46] and in vivo [16,20,46] are
heterogeneousand mayhavedifferentbuoyantdensitiesduetotheir
association with different classes of lipoproteins. To determine the
density profiles of the virus particles generated in cell culture and in
humanized mice and to identify the virus fraction sensitive to LPL,
we analyzed these virus preparations fractionated on iodixanol
gradients. This type of gradient is frequently used for the analysis of
lipoproteins and has been used to separate HCV-lipoprotein
complexes from the serum of patients [16].
Concentrated supernatants from Huh7.5 cells were subjected to
isopycnic centrifugation through an iodixanol gradient. The
fractions collected were analyzed for the presence of HCV core
antigen, HCV RNA, ApoB and cholesterol.
For the JFH-1 strain, HCV-RNA was detected at various
concentrations in most fractions of the gradient with a peak at a
density of 1.066 g/ml. HCV core antigen was found mostly in
two peaks, delineating two viral populations (Figure 2A). The first
of these populations banded in the density range of 1.022–
1.036 g/ml and colocalized with most of the Apo B and
cholesterol (detected in the density range 1.017–1.04 g/ml)
Figure 1. LPL inhibits cell infection by the JFH-1 and J6/JFH-1
strains produced in vitro and in vivo in a chimeric uPA-SCID
mouse model. The HCVcc strains JFH-1 (A) and J6/JFH-1 (B) were
produced in the Huh7.5 hepatoma cell line. Cells were incubated with
(or without) LPL for 30 min at 4uC and then with virus preparations for
2 h at 37uC to allow infection. RNA was extracted from cells 24 h post
infection and HCV RNA was quantified by RT-qPCR. The data obtained
were normalized with respect to levels of GADPH. The mJFH-1 (A) and
mJ6/JFH-1 (B) correspond to HCVcc strains produced in chimeric uPA-
SCID mice into which we transplanted human hepatocytes. Serum
samples collected from infected mice were pooled and their capacity to
infect Huh7.5 cells was assessed in the presence and absence of LPL, as
outlined above. Cells infected in the absence (black bar) and in the
presence of LPL (gray bar). The data are expressed as the amount of
HCV RNA detected in cells infected in the presence of LPL as compared
with the amount of HCV RNA in cells infected in the absence of LPL,
expressed as a percentage.
doi:10.1371/journal.pone.0026637.g001
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HCV core antigen, partly coincided with HCV RNA and was
recovered at a mean density of 1.086 g/ml. ApoB and cholesterol
were also found at this density, but in lower concentrations than
in the lower-density virus population. A similar distribution of the
viral RNA was obtained for the J6/JFH-1strain (Figure 2E). For
both virus strains, fractions corresponding to the main HCV
RNA peak were of relatively low infectivity (Figure 2F). Thus,
there was probably a large excess of RNA over infectious virus
particles in this peak. Indeed, the high density population was
found to be about 8 to 10 times less infectious than the low-
density viral peak. These findings confirm previous observations
of an inverse relationship between virus density and infectivity
[37,38,46,47].
The human hepatoma cell line Huh7.5 does not display typical
lipoprotein metabolism. The virus particles produced in this in vitro
model may therefore have lipoprotein compositions and physico-
chemical properties different from those of virus particles
produced in primary hepatocytes. As the association of HCV in
the blood of chimeric mice with ApoB-containing lipoproteins is
similar to that observed in the serum of patients infected with
HCV [36], the properties of virus particles produced in this model
Figure 2. Iodixanol gradient analysis of the JFH-1 and J6/JFH-1 strains produced in vitro and in vivo. The supernatants from infected
Huh7.5 cells producing JFH-1 (JFH-1, shown in A and B) and J6/JFH-1 (shown in E) were subjected to isopycnic centrifugation through iodixanol
gradients, as described in Materials and Methods. Pooled serum samples from the chimeric uPA-SCID mice were also subjected to centrifugation on
the same type of gradient. Representative profiles are shown in C and D for mice inoculated with JFH-1 (mJFH-1) and in F for mice inoculated with J6/
JFH-1 (mJ6/JFH-1). HCV core antigen in gradient fractions was quantified by ELISA, HCV RNA was quantified by RT-qPCR, and ApoB and cholesterol
were determined by ELISA. Infectivity for fractionated J6/JFH-1 (representative for both strains) grown in Huh7.5 cells is shown in E and that for the
corresponding mouse serum (mJ6/JFH-1) is shown in F. The fractions (25 ml) were used to infect Huh7.5 cells. Cells were incubated for 48 h at 37uC;
total RNA was then extracted and HCV-RNA levels were quantified by RT-qPCR. The results were normalized, taking into account the initial HCV-RNA
content in each sample analyzed, as determined by RT-qPCR, and are expressed as a ratio of these two values.
doi:10.1371/journal.pone.0026637.g002
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blood of HCV-infected patients.
We compared the properties of virus particles produced in vitro
and in vivo by analyzing sera from HCV-infected mice on iodixanol
gradients. HCV from infected chimeric mice, such as the cell
culture-derived HCVcc, banded mainly in two peaks in the
iodixanol gradients. For the JFH-1 strain recovered from mice
(mJFH-1), a low–density virus population appeared as a very small
peak of HCV-core antigen, banding at a density of 1.019 g/ml,
whereas a higher density mJFH-1 population was recovered as a
peak containing both HCV RNA and core antigen at a density of
1.053 g/ml (Figure 2C). Both viral peaks colocalized with
cholesterol and ApoB, although most of the ApoB was associated
with the low-density population (Figure 2D). Low density HCVcc
population produced in mice was 15 times more infectious than
higher density population from the same gradient (Figure 2F).
When compared viruses produced in vivo and in vitro the first, low
density virus population identified in fractionated mice sera was
about twice as infectious as the corresponding population from the
inoculum (Fig. 2F). The second, higher density virus peak in
fractionated mice serum containing most of the HCV RNA and
core antigen and had a significantly lower buoyant density than
the corresponding peak from the initial inoculum (1.053 versus
1.066 g/ml and 1.06 versus and 1.14 g/ml, for JFH-1 and J6/
JFH-1, respectively). These changes in viral density corresponded
to an increase in infectivity by a factor of about three (Figure 2F).
Despite all these differences in density, LPL inhibited the
infection of cells by all virus populations, regardless of whether the
viruses were produced in vitro or in vivo (Figure 3A and B).
Influence of LPL on the lipoprotein metabolism of
Huh7.5 cells
LPL has two physiological roles. Firstly, it displays lipolytic
activity, hydrolyzing the primary ester linkages in triacylglycerols
from chylomicrons and VLDL, producing free fatty acids and
monoacylglycerols. Secondly, LPL promotes the cellular uptake of
chylomicron remnants, and cholesterol-rich lipoproteins through
its role as a bridge between lipoproteins and HSPG at the
hepatocyte surface. This function is independent of the catalytic
activity of LPL.
We investigated the mechanisms by which LPL inhibited HCV
infection, by analyzing the influence of LPL on VLDL hydrolysis
and uptake by Huh7.5 cells under the experimental conditions
used for HCV infection. Huh7.5 cells were washed with FCS-free
medium and incubated with LPL on ice. Purified VLDL were then
added and, after 30 min, the cells were transferred to 37uC and
incubated for a further 2 h.
The effect of LPL on VLDL was already observable after 2 h of
incubation, as shown by increases in the levels of both triglycerides
(TG) and total cholesterol (TC) associated with the cells in the
presence of LPL (Figure 4). We used tetrahydrolipstatin (THL), a
specific inhibitor of the catalytic activity of LPL, which blocks the
active site of the enzyme [48], to assess the impact of the lipolytic
function of LPL on lipoprotein uptake.
Hydrolysis of VLDL was illustrated by the increase in TG levels
resulting from the formation of fatty acids and their intracellular
accumulation (Figure 4A). This process was entirely dependent on
lipolysis and was therefore inhibited by THL, but not sensitive to
heparin.
By contrast, the increase in TC after the incubation of cells with
LPL and VLDL showed that the uptake of lipoproteins required
both lipolytic and bridging activities (Figure 4B). Indeed, the
simultaneous addition of THL and LPL abolished the stimulatory
effect of LPL on lipoprotein uptake, by blocking its catalytic
activity. The stimulatory effect of LPL was also abolished by the
addition of heparin, which prevented LPL from associating with
proteoglycans, thus disabling its ‘‘bridging’’ activity.
These data confirmed that, under our experimental conditions,
both enzymatic and bridging activities were involved in the
cellular binding and/or uptake of VLDL and their remnants.
Indeed, the LPL-induced increase in TC associated with these cells
required lipolytic digestion and heparan sulfate for the ‘‘docking’’
of the enzyme during its bridging function.
Mechanism of action of LPL on HCV infection
LPL has two physiological roles, either of which may affect virus
infectivity. Its enzymatic activity might induce changes in the lipid
composition and structure of the virus particles, whereas its
‘‘bridging’’ function might play a role in the inhibitory process,
either binding the virus tightly to the cell surface or directing it to
the abortive infection pathway. We investigated which of these
LPL functions was determinant for the inhibition of HCV
infection, by performing experiments with THL, blocking the
catalytic activity of LPL. The inhibitory effect of LPL on HCVcc
infection was only partially abrogated by THL (Figure 5A). In the
absence of THL, LPL inhibited viral infection by two orders of
magnitude, whereas, in the presence of THL, LPL also decreased
infection levels, but only by one order of magnitude. We
Figure 3. Cell infection with low- and high-density virus
populations from iodixanol gradients in the presence or
absence of LPL. The pooled peak fractions of the low- and high-
density virus populations obtained after centrifugation through
iodixanol gradients of JFH1 grown in cell culture (A) and serum
samples from the m-JFH1 chimeric mouse model (B) (both gradients are
shown in Figure 2) were used to infect cells in the presence or absence
of 1 mg/ml LPL, as described in the Materials and Methods section. Cells
were grown for 48 h at 37uC and HCV RNA was extracted and
quantified by RT-qPCR. The results were normalized with respect to the
cellular gene GAPDH, with the GAPDH Control Kit. The data are
expressed as the amount of HCV RNA detected in cells infected with the
pooled fractions from the two major virus populations in the presence
of LPL as compared with the amount of HCV RNA in cells infected with
the same fractions in the absence of LPL, expressed as a percentage.
doi:10.1371/journal.pone.0026637.g003
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capacity, by measuring intracellular HCV RNA levels, 24 h after
infection (Figure 5B).
These data indicated that the changes in the lipid composition
of the virus particles induced by catalytically active LPL were only
partly responsible for the inhibitory effect of the enzyme on viral
infectivity and suggested a predominant role for the second,
structure-bridging function of LPL. Indeed, exogenously added
LPL enhanced the binding of HCVcc to Huh7.5 cells (at 4uC), as
shown by the increase in HCV-RNA associated with cells
(Figure 6A). This increase was maximal for a concentration of
1–3 mg/ml LPL. Higher concentrations of LPL did not increase
virus binding further and were instead toxic to cells.
The enzyme influenced apparently virus cell entry, as infection
levels were significantly lower following the addition of LPL
during the first 20 min after infection (Figure 6B), and no
significant inhibition was observed when the enzyme was added
at later time points with the maintenance of its levels during cell
culture. These results support the notion that LPL influences
virus binding to the cell membrane and the early stages of HCV
cell entry.
We therefore hypothesized that LPL could either block the
virus at the cell surface, or internalize it by the non productive
pathway, leading to abortive infection. To distinguish between
these two possibilities, we followed the internalization of viral
particles into Huh7.5 cells during first 20 min of infection, by
electron microscopy. For these studies, virus particles produced
in Huh7.5 cells (JFH-1 strain) and secreted into the cell
supernatant were highly concentrated by ultracentrifugation
through a sucrose cushion, as described in the Materials and
Methods section. Huh7.5 cells were infected with the virus in the
presence or absence of LPL and analyzed at the binding stage
(T0) and after 5 min (T5), 10 min (T10) and 20 min (T20) of
incubation at 37uC.
In the absence of immunogold labeling of viral proteins, it was
not possible to localize viral structures to either the vicinity of the
cells or within cells. These observations are consistent with the
lipoprotein structure of the virus. We therefore performed
immunoelectron microscopy (IEM) on fixed cells after various
periods of incubation with HCV, using antibodies directed against
HCV E2 or core proteins, followed by immunogold labeling. We
used this experimental strategy to investigate viral cell entry in the
presence and absence of LPL.
In the absence of LPL, at the initial attachment phase, HCV
was visible only on the outside of the cell, mostly in contact with
the hepatocyte plasma membrane (Figure 7, T0). HCV appeared
in intracellular vesicles after attachment of the virus at 4uC,
Figure 4. Analysis of the influence of LPL on VLDL hydrolysis
and uptake by Huh 7.5 cells. Huh 7.5 cells were washed with
medium without FCS and pre-incubated with LPL on ice. Purified VLDL
were then added and, after 30 min, cells were transferred to 37uC and
incubated for a further 2 h. The effect of LPL on VLDL uptake was
shown by the increase in the amounts of both total triglycerides (TG)
associated with cells in the presence of LPL. Cellular levels of TC and TG
were also assessed in the presence of LPL and THL or heparin. (A)
Hydrolysis of VLDL by LPL increased cellular TG levels due to the
intracellular accumulation of fatty acids. This process was inhibited by
THL, but was insensitive to the action of heparin, as it did not involve
‘‘bridging’’ mechanisms. (B) LPL increased the levels of TC in the cells in
the presence VLDL. The effect of LPL was abolished by adding either
THL, an inhibitor of LPL enzyme activity, or heparin, which prevents LPL
from associating with proteoglycans. Thus, both catalytic and bridging
activities were involved.
doi:10.1371/journal.pone.0026637.g004
Figure 5. The inhibitory effect of LPL on HCVcc infection is only
partly related to its catalytic activity. (A) Huh7.5 cells were pre-
incubated with 1 mg/ml LPL at 4uC in the presence or absence of 50 mg/
ml THL before infection with JFH1. The infected cells were grown for
24 h and HCV RNA was then extracted and quantified by RT-qPCR. (B)
THL does not influence HCV replication. Huh7.5 cells were pre-
incubated with indicated concentrations of THL before cell infection
with JFH-1, as for experiments with LPL. THL was maintained in the
medium for 24 h post infection. HCV RNA was then extracted and
quantified by RT-qPCR. Results are expressed as a percent of RNA as
compared with control cells infected in the absence of LPL and THL.
doi:10.1371/journal.pone.0026637.g005
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periods of incubation (10–20 min) at 37uC, HCV progressed
further into the cell and was seen in vesicles localized in the cell
center (T10), close to lipid droplets, and eventually close to the
nucleus (T20). We chose to label both the HCV E2 and HCV
core proteins, reasoning that the signal for HCV E2 might be lost
at later time points, during viral internalization. However, we
noted that the structures labeled with antibodies against E2 or
core antibodies were identical, at all time points. The identical
distributions of core and E2 suggested that our electron
microscopy analyses followed the internalization of complete
virus particles.
In control experiments, in which detergent-free buffer was used
for the preparation of material for IEM, only the E2 protein was
detected and found to be located outside the cell. Thus, saponin
treatment was required for the intracellular staining of virus
particles, suggesting that this treatment exposed HCV core from
complete virions, as previously reported [15,49].
In the presence of LPL, HCV was observed exclusively
extracellularly, in close proximity to the plasma membrane, at
all time points: T0, T10 and T20 (Figure 8). A very similar
distribution was observed with anti-E2 and anti-core antibodies,
indicating that, even at longer incubation times, complete HCV
particles containing the virus nucleocapsid and envelope were still
attached to the plasma membrane. Immunogold labeling of
uninfected cells with an antibody against LPL was exclusively
confined to the plasma membrane (Figure 8; LPL 10 min),
suggesting that the enzyme also remained bound to the plasma
membrane, or was degraded inside the cell. Uninfected cells
incubated with the buffer used to dissolve LPL alone had a normal
morphology and ultrastructure (data not shown).
We confirmed the specificity of the immunostaining procedure
by performing several control experiments, including the labeling
of infected or non infected cells in the absence of primary
antibodies. No gold labeling was observed when the primary
antibody was omitted or used on non infected cells. Staining with
monoclonal antibodies against Rab-5 and Lamp-1 (instead of anti-
E2 and anti-core) under the same conditions resulted in the
specific labeling of early endosomes and late endosomes/
lysosomes, respectively, with no labeling of any other structures
(Figure S1).
We quantified the gold-labeled HCV core particles within and
outside cells infected in the presence or absence of LPL. These
analyses clearly demonstrated a progressive increase of the number
of intracellular gold-labeled core particles (from T0 to T20 min
post infection) with respect to the number of particles located
outside the cell when infection was carried out in the absence of
LPL (Figure 9A). By contrast, in the presence of LPL, most virus
particles remained extracellular, at all time points tested
(Figure 9B).
These results at the nanometric scale are consistent with an
inhibitory effect of LPL during the early stages of HCV cell entry.
Our observations suggest that LPL neither destroyed the virus
particles nor induced their internalization into structures likely to
direct the virus to abortive infection. Instead, LPL blocked HCV
internalization, firmly binding the virus to the cell surface.
Discussion
In this study we provide evidence that lipoprotein lipase, a key
enzyme in lipoprotein metabolism, inhibits HCV infection. Our
data show that exogenous LPL increases viral attachment to the
cell surface, but strongly inhibits infection of the cell by HCV, by
two mechanisms: lipolytic activity and ‘‘molecular bridging’’,
together leading to the retention of virus particles at the cell
surface. We followed the early stages of HCV infection by
immunoelectron microscopy and demonstrated that virus inter-
nalization into hepatic cells was blocked in the presence of LPL,
which immobilized the virus at the cell surface.
Several studies have highlighted the role of lipoproteins and
lipids in the HCV life cycle (see for review [22,42]. Infectious
HCV circulates in the serum of patients, in association with VLDL
and LDL [13,15,17], which are integral components of HCV
particles [16]. Indeed, the morphogenesis and secretion of
infectious HCV follow the VLDL assembly pathway, with the
secretion of VLDL-associated virions from infected cells [5,8,46].
Lipoproteins associated with virus particles render HCV infec-
tious, as shown in studies in vitro [15,17,18,50] and in vivo [14,20],
promote viral uptake by the lipoprotein receptors LDL-R and/or
SR-BI/Cla1 [10,17,51,52,53] and protect the virus against
neutralizing antibodies [53], which are therefore unable to control
chronic HCV infection [54,55].
Figure 6. LPL affects HCV attachment and early stages of the
virus cell cycle. (A) Effect of LPL on virus attachment to Huh7.5 cells.
Huh7.5 cells were pre-incubated with various concentrations of LPL (1–
9 mg/ml) for 30 min at 4uC. An aliquot of cell culture supernatant
containing JFH-1 was incubated with LPL-pretreated Huh7.5 cells for
30 min at 4uC. The cells were washed and the RNA associated with
them was extracted. HCV RNA was quantified by RT-qPCR. (B) Effect of
LPL on early steps of HCV infection. JFH-1 was first adsorbed onto
Huh7.5 cells by incubation for 45 min at 4uC. Cells were washed with
cold medium to remove any unbound virus. Complete medium,
warmed to 37uC, was then added and incubated with the cells at 37uC.
LPL was added to a concentration of 1 mg/ml at various time points (0,
5, 10, 15 or 20 min) after the transfer of cells to 37uC, with or without
the addition of 50 mg/ml THL to block its enzymatic activity. Cells were
grown for 24 h. RNA was then extracted and HCV RNA was quantified
by RT-qPCR. Results are expressed as a percent of RNA as compared
with control cells infected in the absence of LPL.
doi:10.1371/journal.pone.0026637.g006
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the lipoproteins associated with virus particles in HCV infectivity.
In a previous study, we showed that exogenously added LPL
increased the attachment of authentic HCV from the serum of
patients to different types of cells, including hepatoma cell lines, by
a ‘‘bridging’’ mechanism involving the binding of LPL to virus-
associated lipoproteins and to HSPG at the cell surface [32].
Indeed, virus attachment to the cell surface via LPL required
HSPG at the cell surface: LPL did not bind the virus to HPSG-
deficient or heparinase-digested cells. This ‘‘molecular bridging’’
of HCV to hepatoma cells was mediated by the dimeric form of
LPL and was analogous to the mechanism by which the liver takes
up lipoproteins from the bloodstream [32]. Although LPL
increased the binding of cell culture-produced HCVcc to the
surface of Huh7.5 cells, we observed an inhibitory effect of LPL on
HCVcc infection [32].
These observations led us to analyze further the impact of LPL
on HCV infection. We show here that LPL inhibits cell infection
with two strains of HCV, JFH-1 and J6/JFH-1, which replicate in
hepatoma cells in vitro. The JFH-1 strain was derived from a cloned
genotype 2a HCV RNA from a patient with fulminant hepatitis C
[37], whereas J6/JFH-1 is a chimeric strain in which the genes
encoding the structural proteins, p7 and NS2 are derived from
another virus, also of the 2a genotype (HC-J6) [38]. The
differences in the amino-acid sequences of the envelope proteins
of these two strains may account for the differences in their
interaction with lipoproteins, thereby affecting their overall
physicochemical properties, including slightly different buoyant
density [56]. Despite these potential differences, the infection of
cells with these two HCVcc strains was equally inhibited by LPL.
The HCV particles circulating in patients’ sera during natural
infection have a wide range of buoyant densities, due to their
association with lipoproteins [16]. In addition to the presence of
mixtures of genomes of various sequences, virus particles from
patient sera are associated with lipoproteins of different TRL and
cholesterol contents, accounting for differences in infectivity and
ability to escape the immune response.
Low-density HCV has been shown to be highly infectious in
chimpanzees [14,57] and in cell cultures in vitro [17]. The low-
density HCV particles, LVPs [15], may represent different
Figure 7. Immunoelectron microscopy of the infection of Huh 7.5 cells with HCV in the absence of LPL. The viral preparation (JFH-1) was
concentrated by centrifugation through a sucrose cushion and incubated with Huh7.5 cells at 4uC (T0), before transfer to 37uC and incubation for a
further 5 (T5), 10 (T10), 15 (T15) or 20 (T20) min. Cells collected at all these time points were washed, fixed and stained with monoclonal antibodies,
followed by secondary, colloidal gold-labeled anti-mouse IgG (see Materials and Methods section for details). T0 and T5, immunogold labeling of HCV
E2 envelope glycoprotein with monoclonal AP-33 antibody; T10 and T20, immunogold labeling of HCV core protein with monoclonal ACAP-27
antibody. Asterisks indicate the presence of one silver-enhanced gold particle. ER, endoplasmic reticulum; LD, lipid droplet; M, mitochondrion; Nu,
nucleus.
doi:10.1371/journal.pone.0026637.g007
Inhibition of HCV Infection by Lipoprotein Lipase
PLoS ONE | www.plosone.org 9 October 2011 | Volume 6 | Issue 10 | e26637proportions of the total viral load in the serum [16]. Moreover,
LVPs follow continuous dynamics, which depends on their
production and transfer onto TRL in the circulation [58]. Thus,
authentic HCV produced in the liver not only uses VLDL
assembly, maturation and secretion pathway but also is subjected
to the intra-vascular modeling of virus-associated lipoproteins
[42,58].
Huh7 cells, which serve as model currently used for studies of
HCV infection have important defects in the cellular lipid
metabolism and thus the spectrum of ApoB–containing lipopro-
tein particles assembled and secreted by these hepatoma cells does
not resembles that produced in vivo or in cultured primary human
hepatocytes [43,44]. Indeed, this hepatoma cell line, like HepG2,
secretes relatively dense, lipid-poor ApoB lipoproteins, unlike the
buoyant VLDL secreted in vivo by the human liver [45,59].
Consequently, most of the secreted ApoB lipoproteins have
biophysical properties similar to those of LDL particles, as only
a small percentage of the ApoB produced is fully lipidated and
secreted as mature VLDL. Deficiencies in the transfer of lipids to
the nascent ApoB in hepatoma cell lines leads to degradation of
most of the Apo B produced [45].
The particular lipoprotein composition of virus particles
produced in the in vitro model may render them more sensitive
to LPL than natural virus particles. We therefore investigated
whether LPL could also inhibit cell infection with the same two
virus strains produced under more natural conditions, in primary
human hepatocytes transplanted into chimeric uPA-SCID mice
with normal lipoprotein metabolism. The humanization of
lipoprotein profiles in this mouse model is associated with HCV
infection success [36]. We show that LPL inhibits cell infection
with the viruses produced in cultured Huh7.5 cells or in chimeric
uPA-SCID mice into which primary human hepatocytes are
grafted. The viruses produced in vitro and in vivo were found to be
equally sensitive to LPL.
We also analyzed the physicochemical characteristics of viruses
produced in vivo and in vitro, to identify the virus fraction sensitive
to LPL. By ultracentrifugation through iodixanol gradients, we
separated both HCVcc strains produced in Huh 7.5 cells, into
essentially two virus populations, as determined by the distribution
of HCV core antigen. Both these virus populations colocalized
with ApoB and cholesterol and their densities indicated that they
were associated with lipoproteins. The low-density viral population
was about 10 times more infectious than the higher density
population for viruses produced in vitro and about 15 times for
viruses produced in vivo, despite higher core antigen and HCV
RNA content in high density population. These observations are
Figure 8. Immunoelectron microscopy of the infection of Huh 7.5 cells in the presence of LPL. Huh7.5 cells were pre-incubated with
1 mg/ml LPL, as described in Materials and Methods. The viral preparation, concentrated by centrifugation through a sucrose cushion, was incubated
with cells at 4uC (T0), then transferred to 37uC and incubated for a further 5 (T5), 10 (T10), 15 (T15) or 20 (T20) min. Cells were washed, fixed and
stained with anti-E2 (AP-33) or anti-core (ACAP-27) monoclonal antibodies, followed by secondary, colloidal gold-labeled anti-mouse IgG. LPL 10 min
is a representative view of uninfected cells, pretreated with LPL at 4uC and subsequently for 10 min at 37uC, before immunogold labeling with anti-
LPL antibodies and processing for TEM. T0, T10 and T20, show immunogold labeling with antibodies directed against HCV E2 (T0) and core protein
(T10 and T20). Asterisks denote the presence of one silver-enhanced gold particle. CCP, clathrin-coated pit; CV, clathrin vesicle; M, mitochondrion.
doi:10.1371/journal.pone.0026637.g008
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RNA peak for HCVcc strains does not coincide with virus
infectivity and that RNA is present in a large excess with respect to
the number of infectious virus particles in higher-density fractions.
These probably encapsidated particles contain HCV RNA and
core protein but fewer of the virus-associated lipoproteins required
for virus infectivity. In fractionated mouse sera the high-density
viral peak also contained most of the HCV RNA and core antigen
but had a lower density than the corresponding peaks for virus
strains produced in vitro. This virus population was about three
times more infectious than the corresponding peak in the
inoculum.
These findings are consistent with previous observations that
viruses produced in vivo or in cultured primary human hepatocytes
are of lower density than those produced in hepatoma cell culture
[20,46,60] and support the notion that the infectivity of virus
particles is inversely correlated with their density and thus depends
on the lipoprotein composition of the virus. Both HCV produced
in vitro and in vivo are associated with ApoB-lipoproteins and
contain ApoE, and both apolipoproteins are required for virus
infectivity [5,7,8,9,15,16,50,61,62]. Moreover, mature virions
have high levels of cholesterol and sphingolipid, the ratio of which
is crucial for virus stability: the depletion of cholesterol and the
hydrolysis of sphingolipids decrease virus internalization and
infectivity [18,19]. In addition, glycosaminoglycans and lipopro-
tein receptors play essential role in HCV cell entry and initiation of
infection and thus lipoprotein composition of virus particles is
determinant for virus infectivity. Indeed, three of the major
molecules mediating HCV cells entry SR-BI, LDL-R and HSPG
interacts with virus associated lipids and lipoproteins [22].
In our study, LPL inhibited infection with ‘‘low-density’’ and
‘‘high-density’’ viral populations isolated from cell supernatants or
from ‘‘humanized’’ mouse sera. This observation suggests that the
density of the virus, and thus the biochemical composition of the
lipoproteins associated with virus particles, does not significantly
influence the effect of LPL on HCV infectivity. Indeed, LPL also
interacts in vivo with various ApoB-containing lipoproteins, such as
LDL, VLDL, chylomicrons and their remnants, with their diverse
lipid compositions and different biophysical characteristics [24].
LPL essentially has two biological functions [23,26,28,30,63].
First, LPL hydrolyzes the triglycerides in TRL, such as
chylomicrons and VLDL, providing free fatty acids for internal-
ization, via the CD36 receptor, into cells in peripheral tissues
[23,30]. Lipolysis is activated by ApoC2, an essential cofactor of
LPL, whereas ApoC3 inhibits this process [64]. LPL is functional
in a dimeric form: LPL dimers are tethered to HSPG or GPIHBP1
at the endothelial surface. GPIHBP1 has recently been identified
as a key platform for the LPL-mediated lipolysis of TRL on the
microvascular endothelium [65].
In addition to hydrolyzing TRL on the microvascular
endothelium, LPL targets lipoproteins and their remnants to the
liver and mediates their uptake by heptocytes. Indeed, the liver is a
major organ for the clearance of ApoB-containing and ApoE-
enriched lipoproteins and their remnants [30,63]. In particular,
the hepatocyte HSPG chains (mainly syndecan-1) binding the
enzyme display a much stronger ligand affinity than HSPG in
other tissues [27,30]. This explains why the injection of exogenous
LPL results in the rapid hepatic clearance of lipoproteins [24]. The
hepatic uptake of chylomicrons and VLDL from the bloodstream,
via LPL, involves a second LPL function, known as ‘‘molecular
bridging’’, in which a bridge is formed between the TRL particle
and HSPG at the cell surface. HSPG can mediate subsequent
lipoprotein internalization alone [27,29,30,66] or in concert with
the lipoprotein receptors LRP, LDL-R, [23,24,26] and SR-BI
[31].
We performed a series of control experiments to assess the
impact of LPL on lipoprotein metabolism in hepatoma cells. We
found that, under our experimental conditions, the enzyme
increased the cellular uptake of both total cholesterol and
triglycerides from VLDL substrate, and that the mechanisms of
uptake involved were different (Figure 4). Indeed, the uptake of
VLDL (and their remnants) involved both lipolysis and bridging
mechanisms, whereas triglyceride uptake was dependent exclu-
sively on the enzymatic activity of LPL.
Thus, the inhibitory effect of LPL on HCV infection may be
related either to its enzymatic activity, inducing changes in the
composition of virus-associated lipoproteins, or to its structural,
‘‘bridging’’ function, independent of lipolysis.
It has been reported that LPL from Pseudomonas aeruginosa
displays strong virolytic activity against HCV from patient sera
[67]. However, we have previously shown that LPL from
Pseudomonas sp. neither affects HCV binding to cells nor inhibits
HCV infection [32]. Thus, the effect of LPL on HCV infectivity is
specific to bovine LPL, which closely resembles the human
enzyme. Our control experiments excluded the possibility of a
direct virolytic effect of LPL on HCV: the infectious potential of
JFH-1 was not significantly decreased by incubation of the virus
preparation with 1 mg/ml LPL in vitro for 4 h at 37uC before
infection [32]). In another study, the in vitro digestion of HCVcc
with much higher concentrations of bovine LPL (up to 500 mg/ml)
induced changes in virus composition and direct inactivation of
the virus [68]. We used a low LPL concentration (1 mg/ml),
similar to the physiological levels currently used in lipoprotein
metabolism studies. This concentration gave the significant
Figure 9. Quantitative analyses of immunoelectron microsco-
py. Cells were infected and processed as for Figures 7 and 8. HCV-
bound gold particles after staining with anti-core antibodies were
quantified in Huh7.5 cells infected in the absence (panel A) and
presence (panel B) of LPL. For each condition and each time point
indicated, 30 cells were analyzed, and the number of gold particles
present outside (dark gray) and within (light gray) cells is reported. Data
are expressed as means6SD.
doi:10.1371/journal.pone.0026637.g009
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our experimental conditions, the enzyme was prebound to cells at
4uC and its levels were maintained during virus infection. In these
conditions, LPL decreased HCV infection levels by two levels of
magnitude.
Our observations suggest that the enzymatic activity of LPL
against virus-associated lipids was only partly responsible for the
inhibition of HCV infection, because enzymatically inactive LPL
decreased infection levels by a factor of 10. Indeed, the effect of
LPL on HCV infectivity was only partly abrogated by THL, a
specific lipase inhibitor that also abolished the effect of LPL on
VLDL uptake into Huh7 cells. THL is an active site inhibitor that
binds to LPL covalently to form a stable complex, inducing
tetramerization of the enzyme [48]. THL does not influence LPL
binding to HSPG, because the enzyme-inhibitor complex has the
same affinity for heparin as active LPL, and facilitates hepatic
TRL binding and clearance independently of its catalytic function
[48,69]. As THL only partly (by one order of magnitude)
decreased the inhibitory effect of LPL, we hypothesized that the
bridging/binding activity of LPL was involved in the inhibition of
HCV infection.
Apparently, there is no correlation between the bridging
function and lipolytic activity. Indeed, naturally occurring
enzymatically inactive genetic variants of human LPL, display
normal bridging function [70]. Consistent with this notion, the
anti-LPL antibody 5D2, which blocks both functions of the
enzyme, completely abolished the effect of LPL [32].
Our immunoelectron microscopy studies made it possible to
follow, for the first time, the early steps of Huh7.5 cell infection.
We used immune labeling with both anti-E2 and anti-core
antibodies and colloidal gold-labeled anti-mouse IgG. In the
absence of LPL, the virions were detected within cells as soon as
5 min after infection. Most of the virus particles were detected
within cells 20 min after infection.
Identical patterns of staining were obtained with the anti-E2
and anti-core antibodies, consistent with the internalization of
complete HCV virions. Nevertheless when detergent-free buffer
was used, only extracellular viral particles were observed, and
these particles were stained with anti-E2, but not with anti-core
antibodies. Thus HCV core was probably exposed due to the
detergent treatment, consistent with the pre-embedding strategy
used for IEM, and with earlier reports showing that core particles
can be detected with anti-core antibody after the delipidation of
HCV virions with detergents [15,49].
When HCV infection was carried out in the presence of LPL,
the virus particles were not detected inside the cells at any time
point, with either anti-E2 or anti-core antibodies, whereas both
LPL and virus particles were detected at the cell surface. Overall,
our findings clearly indicate that LPL inhibits HCV internalization
by immobilizing virus particles at the cell surface.
Our observations suggest that HCV internalization might be
rapid, whereas in vitro infection can be neutralized by anti-CD81
antibodies even 30 min after virus binding [71,72]. However, it
has recently been shown that virus particles of different densities
may initiate infections at different rates [73]. Thus, the HCV
internalization observed in our study by immunelectron micros-
copy may correspond to cell infection with one of the virus
populations present in our heterogeneous inoculum, reflecting the
initial phase of a much longer infection process.
The molecular mechanisms underlying the tight binding of
viruses to the cell surface in the presence of LPL require further
investigation. The lipolytic activity of LPL does not destroy the
virus structure, but LPL may (i) cause the remodeling of
lipoproteins associated with the virus, resulting in the formation
of smaller and denser lipoproteins, (ii) change the balance
between ApoB and ApoC’s in HCV particles, this ratio being
determinant for virus cell entry, (iii) induce conformational
changes in ApoB, and/or ApoE, thereby affecting their reactivity
with lipoprotein receptors [30,62,74,75]. These changes might
enhance the interaction of virus particles with cells and block
their internalisation.
LPL might also increase virus attachment to hepatocyte HSPG,
which is considered to be the HCV-attachment factor at the
human hepatocyte membrane [76,77]. LDL and other ApoB-
containing lipoproteins bind weakly to vascular proteoglycans, but
much more tightly via their lipids to proteoglycan -bound LPL.
The non catalytic, bridging function of LPL therefore facilitates
their retention in the vessel wall by extracellular matrix
proteoglycans [78,79,80]. HCV retention at the surface of hepatic
cells may thus be governed by similar mechanisms: direct virus
attachment to HSPG, followed by a shift to much stronger virus
binding to HSPG via LPL-bridging.
Collectively, our findings indicate that LPL inhibits HCV
infection by two mechanisms: lipolytic modification of the TRL
associated with virus particles and a predominant effect of the
bridging function, which may act in parallel with lipolysis.
Together, these two functions of LPL facilitate the retention of
the virus at the cell surface, significantly decreasing infection levels.
Thus, molecules targeting the lipoproteins associated with virus
particles could affect HCV infectivity and, as such, could have
implications for future therapeutic approaches based on the
inhibition of HCV infection. Indeed, HCV-lipid interactions may
be attractive targets for the development of antiviral drugs,
because the targeting of essential host cell factors could limit the
development of escape mutations effective against drugs directly
targeting virus components [42].
Supporting Information
Figure S1 Immunoelectron microscopy of uninfected
Huh7.5 cells stained with Rab5 or LAMP-1 antibodies.
Similar procedure to that described in Materials and Methods was
applied to the immuno-gold labeling of Rab5, a marker of early
endosomes and LAMP-1 as a marker of late endosomes and
lysosomes. Asterisks denote vesicles positive for Rab5. White tick
denotes a characteristic lysosomal localization of LAMP-1. D,
desmosome; KF, keratin fibers.
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